Staff View: United in Fight against prOstate cancer (UFO) registry: first results from a large, multi-centre, prospective, longitudinal cohort study of advanced prostate cancer in Asia

United in Fight against prOstate cancer (UFO) registry: first results from a large, multi-centre, prospective, longitudinal cohort study of advanced prostate cancer in Asia

Objectives: To document the management of advanced prostate cancer including diagnosis, prognosis, treatment, and care, in real-world practice in Asia using the United in Fight against prOstate cancer (UFO) registry. Patients and Methods: We established a multi-national, longitudinal, observational...

Full description

Saved in:

Bibliographic Details
Main Authors:	Uemura, Hirotsugu, Ye, Dingwei, Kanesvaran, Ravindran, Chiong, Edmund, Lojanapiwat, Bannakij, Pu, Yeong-Shiau, Rawal, Sudhir Kumar, Razack, Azad Hassan Abdul, Zeng, Hao, Chung, Byung Ha, Md Yusoff, Noor Ashani, Ohyama, Chikara, Kim, Choung Soo, Leewansangtong, Sunai, Tsai, Yuh-Shyan, Liu, Yanfang, Liu, Weiping, van Kooten Losio, Maximiliano, Asinas-Tan, Marxengel
Format:	Article
Published:	Wiley 2020
Subjects:	R Medicine
Online Access:	http://eprints.um.edu.my/24790/ https://doi.org/10.1111/bju.14980
Tags:	Add Tag No Tags, Be the first to tag this record!

id	my.um.eprints.24790
record_format	eprints
spelling	my.um.eprints.247902020-06-11T03:26:23Z http://eprints.um.edu.my/24790/ United in Fight against prOstate cancer (UFO) registry: first results from a large, multi-centre, prospective, longitudinal cohort study of advanced prostate cancer in Asia Uemura, Hirotsugu Ye, Dingwei Kanesvaran, Ravindran Chiong, Edmund Lojanapiwat, Bannakij Pu, Yeong-Shiau Rawal, Sudhir Kumar Razack, Azad Hassan Abdul Zeng, Hao Chung, Byung Ha Md Yusoff, Noor Ashani Ohyama, Chikara Kim, Choung Soo Leewansangtong, Sunai Tsai, Yuh-Shyan Liu, Yanfang Liu, Weiping van Kooten Losio, Maximiliano Asinas-Tan, Marxengel R Medicine Objectives: To document the management of advanced prostate cancer including diagnosis, prognosis, treatment, and care, in real-world practice in Asia using the United in Fight against prOstate cancer (UFO) registry. Patients and Methods: We established a multi-national, longitudinal, observational registry of patients with prostate cancer presenting to participating tertiary care hospitals in eight Asian countries. A total of 3636 eligible patients with existing or newly diagnosed high-risk localised prostate cancer (HRL), non-metastatic biochemically recurrent prostate cancer (M0), or metastatic prostate cancer (M1), were consecutively enrolled and are being followed-up for 5 years. Patient history, demographic and disease characteristics, treatment and treatment decisions, were collected at first prostate cancer diagnosis and at enrolment. Patient-reported quality of life was prospectively assessed using the European Quality of Life-five Dimensions, five Levels (EQ-5D-5L) and Functional Assessment of Cancer Therapy for Prostate Cancer questionnaires. In the present study, we report the first interim analysis of 2063 patients enrolled from study start (15 September 2015) until 18 May 2017. Results: Of the 2063 enrolled patients, 357 (17%), 378 (19%), and 1328 (64%) had HRL, M0 or M1 prostate cancer, respectively. The mean age at first diagnosis was similar in each group, 56% of all patients had extracapsular extension of their tumour, 28% had regional lymph node metastasis, and 53% had distant metastases. At enrolment, 62% of patients had at least one co-morbidity (mainly cardiovascular disease or diabetes), 91.8% of M1 patients had an Eastern Cooperative Oncology Group performance score of <2 and the mean EQ-5D-5L visual analogue score was 74.6–79.6 across cohorts. Treatment of M1 patients was primarily with combined androgen blockade (58%) or androgen-deprivation therapy (either orchidectomy or luteinising hormone-releasing hormone analogues) (32%). Decisions to start therapy were mainly driven by treatment guidelines and disease progression. Decision to discontinue therapy was most often due to disease progression (hormonal drug therapy) or completion of therapy (chemotherapy). Conclusion: In the UFO registry of advanced prostate cancer in Asia, regional differences exist in prostate cancer treatment patterns that will be explored more deeply during the follow-up period; prospective follow-up is ongoing. The UFO registry will provide valuable descriptive data on current disease characteristics and treatment landscape amongst patients with prostate cancer in Asia. © 2019 The Authors BJU International Published by John Wiley & Sons Ltd on behalf of BJU International Wiley 2020 Article PeerReviewed Uemura, Hirotsugu and Ye, Dingwei and Kanesvaran, Ravindran and Chiong, Edmund and Lojanapiwat, Bannakij and Pu, Yeong-Shiau and Rawal, Sudhir Kumar and Razack, Azad Hassan Abdul and Zeng, Hao and Chung, Byung Ha and Md Yusoff, Noor Ashani and Ohyama, Chikara and Kim, Choung Soo and Leewansangtong, Sunai and Tsai, Yuh-Shyan and Liu, Yanfang and Liu, Weiping and van Kooten Losio, Maximiliano and Asinas-Tan, Marxengel (2020) United in Fight against prOstate cancer (UFO) registry: first results from a large, multi-centre, prospective, longitudinal cohort study of advanced prostate cancer in Asia. BJU International, 125 (4). pp. 541-552. ISSN 1464-4096 https://doi.org/10.1111/bju.14980 doi:10.1111/bju.14980
institution	Universiti Malaya
building	UM Library
collection	Institutional Repository
continent	Asia
country	Malaysia
content_provider	Universiti Malaya
content_source	UM Research Repository
url_provider	http://eprints.um.edu.my/
topic	R Medicine
spellingShingle	R Medicine Uemura, Hirotsugu Ye, Dingwei Kanesvaran, Ravindran Chiong, Edmund Lojanapiwat, Bannakij Pu, Yeong-Shiau Rawal, Sudhir Kumar Razack, Azad Hassan Abdul Zeng, Hao Chung, Byung Ha Md Yusoff, Noor Ashani Ohyama, Chikara Kim, Choung Soo Leewansangtong, Sunai Tsai, Yuh-Shyan Liu, Yanfang Liu, Weiping van Kooten Losio, Maximiliano Asinas-Tan, Marxengel United in Fight against prOstate cancer (UFO) registry: first results from a large, multi-centre, prospective, longitudinal cohort study of advanced prostate cancer in Asia
description	Objectives: To document the management of advanced prostate cancer including diagnosis, prognosis, treatment, and care, in real-world practice in Asia using the United in Fight against prOstate cancer (UFO) registry. Patients and Methods: We established a multi-national, longitudinal, observational registry of patients with prostate cancer presenting to participating tertiary care hospitals in eight Asian countries. A total of 3636 eligible patients with existing or newly diagnosed high-risk localised prostate cancer (HRL), non-metastatic biochemically recurrent prostate cancer (M0), or metastatic prostate cancer (M1), were consecutively enrolled and are being followed-up for 5 years. Patient history, demographic and disease characteristics, treatment and treatment decisions, were collected at first prostate cancer diagnosis and at enrolment. Patient-reported quality of life was prospectively assessed using the European Quality of Life-five Dimensions, five Levels (EQ-5D-5L) and Functional Assessment of Cancer Therapy for Prostate Cancer questionnaires. In the present study, we report the first interim analysis of 2063 patients enrolled from study start (15 September 2015) until 18 May 2017. Results: Of the 2063 enrolled patients, 357 (17%), 378 (19%), and 1328 (64%) had HRL, M0 or M1 prostate cancer, respectively. The mean age at first diagnosis was similar in each group, 56% of all patients had extracapsular extension of their tumour, 28% had regional lymph node metastasis, and 53% had distant metastases. At enrolment, 62% of patients had at least one co-morbidity (mainly cardiovascular disease or diabetes), 91.8% of M1 patients had an Eastern Cooperative Oncology Group performance score of <2 and the mean EQ-5D-5L visual analogue score was 74.6–79.6 across cohorts. Treatment of M1 patients was primarily with combined androgen blockade (58%) or androgen-deprivation therapy (either orchidectomy or luteinising hormone-releasing hormone analogues) (32%). Decisions to start therapy were mainly driven by treatment guidelines and disease progression. Decision to discontinue therapy was most often due to disease progression (hormonal drug therapy) or completion of therapy (chemotherapy). Conclusion: In the UFO registry of advanced prostate cancer in Asia, regional differences exist in prostate cancer treatment patterns that will be explored more deeply during the follow-up period; prospective follow-up is ongoing. The UFO registry will provide valuable descriptive data on current disease characteristics and treatment landscape amongst patients with prostate cancer in Asia. © 2019 The Authors BJU International Published by John Wiley & Sons Ltd on behalf of BJU International
format	Article
author	Uemura, Hirotsugu Ye, Dingwei Kanesvaran, Ravindran Chiong, Edmund Lojanapiwat, Bannakij Pu, Yeong-Shiau Rawal, Sudhir Kumar Razack, Azad Hassan Abdul Zeng, Hao Chung, Byung Ha Md Yusoff, Noor Ashani Ohyama, Chikara Kim, Choung Soo Leewansangtong, Sunai Tsai, Yuh-Shyan Liu, Yanfang Liu, Weiping van Kooten Losio, Maximiliano Asinas-Tan, Marxengel
author_facet	Uemura, Hirotsugu Ye, Dingwei Kanesvaran, Ravindran Chiong, Edmund Lojanapiwat, Bannakij Pu, Yeong-Shiau Rawal, Sudhir Kumar Razack, Azad Hassan Abdul Zeng, Hao Chung, Byung Ha Md Yusoff, Noor Ashani Ohyama, Chikara Kim, Choung Soo Leewansangtong, Sunai Tsai, Yuh-Shyan Liu, Yanfang Liu, Weiping van Kooten Losio, Maximiliano Asinas-Tan, Marxengel
author_sort	Uemura, Hirotsugu
title	United in Fight against prOstate cancer (UFO) registry: first results from a large, multi-centre, prospective, longitudinal cohort study of advanced prostate cancer in Asia
title_short	United in Fight against prOstate cancer (UFO) registry: first results from a large, multi-centre, prospective, longitudinal cohort study of advanced prostate cancer in Asia
title_full	United in Fight against prOstate cancer (UFO) registry: first results from a large, multi-centre, prospective, longitudinal cohort study of advanced prostate cancer in Asia
title_fullStr	United in Fight against prOstate cancer (UFO) registry: first results from a large, multi-centre, prospective, longitudinal cohort study of advanced prostate cancer in Asia
title_full_unstemmed	United in Fight against prOstate cancer (UFO) registry: first results from a large, multi-centre, prospective, longitudinal cohort study of advanced prostate cancer in Asia
title_sort	united in fight against prostate cancer (ufo) registry: first results from a large, multi-centre, prospective, longitudinal cohort study of advanced prostate cancer in asia
publisher	Wiley
publishDate	2020
url	http://eprints.um.edu.my/24790/ https://doi.org/10.1111/bju.14980
_version_	1674066729253208064
score	13.211869

United in Fight against prOstate cancer (UFO) registry: first results from a large, multi-centre, prospective, longitudinal cohort study of advanced prostate cancer in Asia

Similar Items